Tag & Associates

Description

Founded in 1998, we are recognized reimbursement experts who believe that: Our manufacturer clients include early stage inventor owned companies, small, mid and large cap biotechs, and global pharmaceutical companies. We also serve professional societies and not-for-profit organizations with a health care focus, and we advise venture capital firms and merchant banks who invest in life sciences. Advertising, public relations and public affairs firms with health industry clients also engage our services for themselves and their clients. Howard Tag, JD has been in the forefront of shaping payment policy for new medical technologies since 1985. Prior to establishing Tag & Associates in 1998, Howard was Executive Vice President/COO of S&FA, Incorporated and its successor company, PAREXEL International Medical Marketing Services. S&FA was a pioneer in the field of reimbursement planning and problem solving, and in the design and operation of patient assistance programs (PAPs). Howard was actively involved in obtaining reimbursement for hundreds of drugs and devices and was responsible for dozens of favorable government and private insurance coverage policies for his clients' technologies. PAPs designed by S&FA brought free or discounted treatments to thousands of patients. Before joining S&FA, Howard was Executive Director of the New York Legislature's Joint Committee on Consumer Protection and Washington Counsel to the J.C. Penney Company for its retail and mail order pharmacies. He is a member of the District of Columbia and New York State Bars, Food and Drug Law Institute, American Health Lawyers Association, the Health Law Committee of the DC Bar Association and the International Society for Pharmacoeconomics and Outcomes Research. Elan Rubinstein, Pharm.D., MPH is Senior Consultant to Tag & Associates. Since 1989, he has provided managed care marketing leadership to manufacturers and distributors of pharmaceuticals, biotechnology, and biological products. Elan is also frequently consulted by employer benefit managers for assistance with pharmaceutical benefit design issues. Investors and technology developers engage Elan ’s services for merger and acquisition guidance or product licensing situation/opportunity assessments, strategic planning, and market positioning. Companies or technologies involved with rare or complex diseases, high cost per treatment, issues related to route of administration, and extraordinary payer controls typically characterize the focus of his assignments. Elan maintains relationships with leaders in the specialty pharmacy and disease management communities to assist with solutions on these issues. Examples of Elan ’s recent consulting assignments include: Biotechnology manufacturers: Market research, market modeling, product positioning, business development, disease management, data acquisition and customer partnering strategies for large biotech, pharma (oncology) biological and diagnostic manufacturers.

Products & services

Similar companies nearby